amr industry alliance

uniting to act on antimicrobial resistance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

read more

We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:

Invest in R&D to meet public health needs with new innovative diagnostics & treatments
Improve access to high-quality antibiotics and ensuring that new ones are available to all
Work to reduce the development of antimicrobial resistance
Support measures to reduce environmental impact from production of antibiotics

shared goals

We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.

progress report

We are working on our first progress report that will be published in January 2018. This report will serve to benchmark our progress, set targets for the future and identify gaps where further efforts may be required. Stay tuned!

in action

Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.

latest news

08/06/2018

Multiple Alliance Members Co-sign the Canadian Declaration on Antimicrobial Resistance

The International Council of Biotechnology Associations (ICBA) supports the Canadian Declaration on Combatting Antimicrobial Resistance, signed by biopharmaceutical and diagnostic companies in Canada...

Read more
18/01/2018

Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come

The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The re...

Read more
18/05/2017

New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance

New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to curb antimicrobial resistance....

Read more

amr in numbers

AMR Impact

Life-sciences at the forefront of the battle against AMR

Development of National Action Plans

R&D

Biotechs

Diagnostics

from the blog

Posted on 12/07/2018
By Thomas Cueni, Director General, IFPMA, Chair, AMR Industry Alliance

Drugs companies are rising to the challenges of research into superbugs

This letter was first published on the Financial Times on 4th July 2018, in response to the article titled "Pharma sector failing to tackle superbugs, says O’Neill" (26th June 2018) I respectfully disagree with Jim O’Neill’s comments on pharmaceutical companies’ inaction on combating ant...

Read more view all

stay informed

Subscribe to receive our updates

  • I consent to the storage of my data according to the Privacy Policy